Global /United Kingdom /Healthcare /Medical Devices /PRM
chevron_leftBack
Proteome Sciences plc logo

Proteome Sciences plc

PRM
LSE: PRM Delayed
1GBX -3.6%
0.0178 USD
As of 13 June 2026, Proteome Sciences plc has a market cap of $6.48M USD, ranking #43401 globally and #988 in the United Kingdom. It ranks #3842 in the Healthcare sector, and #809 in the Medical Devices industry.
Global Rank
43401
Country Rank
988
Sector Rank
3842
Industry Rank
809
Key Stats
Market Cap
$6.48MUSD
4.84M GBP
Enterprise Value
$26.55MUSD
19.83M GBP
Revenue (TTM)
$5.03MUSD
3.76M GBP
EBITDA (TTM)
-$3.33MUSD
-2.49M GBP
Net Income (TTM)
-$4.1MUSD
-3.06M GBP
EBITDA Margin
-66%
Profit Margin
-81%
PS Ratio
1.3
PB Ratio
-0.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Mariola Sohngen open_in_new
Employees
32
Founded
1993
Website
proteomics.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-3.6% 0.7% -20% -34% -43% -55%
Upcoming Earnings
Earnings Date
Thu, Jun 25

News

Loading...

Markets

Exchange Ticker Price
London Stock Exchange
MIC: XLON
PRIMARY
PRM
Proteome Sciences PLC
ISIN: GB0003104196
Shares Out.:
350.725M1 Shares Float: 294.791M2
TV:
SA:
YF:
GF:
BA:
PRM
MS:
1 GBX
OTC Markets
MIC: OTCM
PMSNF
Proteome Sciences PLC
ISIN: GB0003104196
Shares Out.:
295.182M1 Shares Float: 255.848M2
TV:
SA:
YF:
GF:
BA:
MS:
0.0449 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Proteome Sciences plc

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

Similar Companies

Industry: Medical Devices (United Kingdom)
Name
Market Cap diff.
PE
$13.24B
9.88B GBP
204K%
21.8
CTEC
$5.69B
4.25B GBP
88K%
34.0
LIVN
$3.22B
50K%
-
NVCR
$1.38B
21K%
-
$723.95M
540.36M GBP
11K%
55.3
TSTL
$239.21M
178.54M GBP
4K%
22.9
Industry: Medical Devices (Global)
Name
Market Cap diff.
PE
$173.27B
3M%
25.8
$160.73B
2M%
56.7
$159.07B
2M%
25.6
DHR
$126.55B
2M%
34.7
SYK
$120.69B
2M%
38.3
MDT
$101.9B
2M%
22.2
chevron_leftBack